

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BVF PARTNERS L P/IL</u> (Last) (First) (Middle) 44 MONTGOMERY STREET 40TH FL (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/18/2020	3. Issuer Name and Ticker or Trading Symbol <u>Olema Pharmaceuticals, Inc.</u> [<u>OLMA</u>]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) See Remarks	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A-1 Convertible Preferred Stock ⁽¹⁾	(5)	(5)	Common Stock, \$0.0001 par value	1,129,404	(5)	D ⁽²⁾	
Series A-1 Convertible Preferred Stock ⁽¹⁾	(5)	(5)	Common Stock, \$0.0001 par value	881,156	(5)	D ⁽³⁾	
Series A-1 Convertible Preferred Stock ⁽¹⁾	(5)	(5)	Common Stock, \$0.0001 par value	185,908	(5)	D ⁽⁴⁾	
Series B Convertible Preferred Stock ⁽¹⁾	(6)	(6)	Common Stock, \$0.0001 par value	889,186	(6)	D ⁽²⁾	
Series B Convertible Preferred Stock ⁽¹⁾	(6)	(6)	Common Stock, \$0.0001 par value	673,281	(6)	D ⁽³⁾	
Series B Convertible Preferred Stock ⁽¹⁾	(6)	(6)	Common Stock, \$0.0001 par value	101,784	(6)	D ⁽⁴⁾	
Series C Convertible Preferred Stock ⁽¹⁾	(7)	(7)	Common Stock, \$0.0001 par value	760,155	(7)	D ⁽²⁾	
Series C Convertible Preferred Stock ⁽¹⁾	(7)	(7)	Common Stock, \$0.0001 par value	522,403	(7)	D ⁽³⁾	
Series C Convertible Preferred Stock ⁽¹⁾	(7)	(7)	Common Stock, \$0.0001 par value	73,399	(7)	D ⁽⁴⁾	

1. Name and Address of Reporting Person* <u>BVF PARTNERS L P/IL</u> (Last) (First) (Middle) 44 MONTGOMERY STREET		
---	--	--

40TH FL

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BIOTECHNOLOGY VALUE FUND L P

(Last) (First) (Middle)

44 MONTGOMERY STREET
40TH FL

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BVF I GP LLC

(Last) (First) (Middle)

44 MONTGOMERY ST., 40TH FLOOR

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BIOTECHNOLOGY VALUE FUND II LP

(Last) (First) (Middle)

44 MONTGOMERY STREET
40TH FL

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BVF II GP LLC

(Last) (First) (Middle)

44 MONTGOMERY ST., 40TH FLOOR

(Street)

SAN FRANCISCO CA 94104

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Biotechnology Value Trading Fund OS LP

(Last) (First) (Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND E9 KY1-1104
CAYMAN

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BVF Partners OS Ltd.

(Last) (First) (Middle)

P.O. BOX 309 UGLAND HOUSE

(Street)

GRAND E9 KY1-1104
CAYMAN

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BVF GP HOLDINGS LLC

(Last) (First) (Middle)

44 MONTGOMERY ST., 40TH FLOOR

(Street)

SAN CA 94104
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BVF INC/IL

(Last) (First) (Middle)

44 MONTGOMERY STREET
40TH FL

(Street)

SAN CA 94104
FRANCISCO

(City) (State) (Zip)

1. Name and Address of Reporting Person*

LAMPERT MARK N

(Last) (First) (Middle)

44 MONTGOMERY STREET
40TH FL

(Street)

SAN CA 94104
FRANCISCO

(City) (State) (Zip)

Explanation of Responses:

1. This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the

securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

5. Effective upon the closing of the Issuer's initial public offering (the "IPO"), each share of the Issuer's Series A-1 Convertible Preferred Stock (the "Series A-1 Preferred") held by the Reporting Persons automatically converts on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, the Series A-1 Preferred was convertible at any time into shares of Common Stock and had no expiration date.

6. Effective upon the closing of the IPO, each share of the Issuer's Series B Convertible Preferred Stock (the "Series B Preferred") held by the Reporting Persons automatically converts on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, the Series B Preferred was convertible at any time into shares of Common Stock and had no expiration date.

7. Effective upon the closing of the IPO, each share of the Issuer's Series C Convertible Preferred Stock (the "Series C Preferred") held by the Reporting Persons automatically converts on a one-for-one basis into the Issuer's Common Stock. Prior to the IPO, the Series C Preferred was convertible at any time into shares of Common Stock and had no expiration date.

Remarks:

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Partners may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned to Partners.

BVF Partners L.P., By:
BVF Inc., its general 11/18/2020
partner, By: /s/ Mark N.
Lampert, President

Biotechnology Value
Fund, L.P., By: BVF 11/18/2020
Partners L.P., its
investment manager, By:
BVF Inc., its general
partner, By: /s/ Mark N.
Lampert, President

BVF I GP LLC, By: BVF 11/18/2020
GP HOLDINGS LLC, its
sole member, By: /s/ Mark
N. Lampert, Chief
Executive Officer

Biotechnology Value Fund
II, L.P., By: BVF Partners 11/18/2020
L.P., its investment
manager, By: BVF Inc., its
general partner, By: /s/
Mark N. Lampert,
President

BVF II GP LLC, By: BVF 11/18/2020
GP HOLDINGS LLC, its
sole member, By: /s/ Mark
N. Lampert, Chief
Executive Officer

BVF Partners OS Ltd., By: 11/18/2020
BVF Partners L.P., its sole
member, By: BVF Inc., its
general partner, By: /s/
Mark N. Lampert,
President

Biotechnology Value
Trading Fund OS LP, By: 11/18/2020
BVF Partners L.P., its
investment manager, BVF
Inc., its general partner,
By: /s/ Mark N. Lampert,
President

BVF GP Holdings LLC, 11/18/2020
By: /s/ Mark N. Lampert,
Chief Executive Officer

BVF Inc., By: /s/ Mark N. 11/18/2020
Lampert, President

/s/ Mark N. Lampert 11/18/2020

** Signature of Reporting Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.